Abstract
As soon as RNA interference (RNAi) was found to work in mammalian cells, research quickly focused on harnessing this powerful endogenous and specific mechanism of gene silencing for human therapy. RNAi uses small RNAs, less than 30 nucleotides in length, to suppress expression of genes with complementary sequences. Two strategies can introduce small RNAs into the cytoplasm of cells, where they are active - a drug approach where double-stranded RNAs are administered in complexes designed for intracellular delivery and a gene therapy approach to express precursor RNAs from viral vectors. Phase I clinical studies have already begun to test the therapeutic potential of small RNA drugs that silence disease-related genes by RNAi. This review will discuss progress in developing and testing small RNAi-based drugs and potential obstacles.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 541-552 |
| Number of pages | 12 |
| Journal | Gene Therapy |
| Volume | 13 |
| Issue number | 6 |
| DOIs | |
| State | Published - Mar 2006 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Drug development
- RNA interference
- Small interfering RNA
- Therapy
ASJC Scopus subject areas
- Molecular Medicine
- Molecular Biology
- Genetics
Fingerprint
Dive into the research topics of 'The silent treatment: SiRNAs as small molecule drugs'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS